vida: extract claims from 2026-04-28-noom-glp1-companion-biomarker-integration-2025

- Source: inbox/queue/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -46,3 +46,10 @@ Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 4
 **Source:** PHTI December 2025 employer report
 
 34% of employers now mandate behavioral support as a coverage condition (up from 10%), and three major payers (Evernorth, Optum Rx, UHC) have operationalized behavioral support as prerequisite infrastructure. This represents market-wide validation that behavioral support improves persistence enough to justify mandatory implementation at the payer level.
+
+
+## Supporting Evidence
+
+**Source:** Noom 2025 performance data, Pharmaceutical Commerce
+
+Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks, with December cohort D30 engagement at 43.6% (10x+ higher than average health/medical/fitness app retention of 4.3%). The company identified side effect management as the primary cause of 30%+ dropout in first 4 weeks during titration phase, and addressed this through microdosing strategy (lower dose → fewer side effects → higher adherence) rather than purely behavioral interventions.

domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md

@@ -45,3 +45,10 @@ WeightWatchers post-bankruptcy strategy (July 2025) explicitly avoids CGM integr
 **Source:** WW International post-bankruptcy clinical strategy, December 2025
 
 WeightWatchers' post-bankruptcy (May 2025) strategy shows selective CGM deployment: Abbott FreeStyle Libre integration for WW Diabetes Program (6-month RCT showing 0.9 HbA1c reduction, 33.8% depression symptom reduction, 62% physical function increase), but NO CGM integration for general GLP-1/obesity Med+ program. The Med+ program uses only AI body scanner and photo-based food tracking—no physical data generation. This selective deployment suggests WW recognizes the atoms-to-bits moat but constrains it to diabetes where CGM reimbursement is established, not extending to the obesity market where Omada (CGM + behavioral + prescribing, profitable, $260M revenue, IPO June 2025) is winning.
+
+
+## Extending Evidence
+
+**Source:** Noom press releases + Pharmaceutical Commerce, December 2025
+
+Noom's December 2025 'Proactive Health Microdose GLP-1Rx' program ($149/month) combines microdosed GLP-1 with at-home biomarker testing every four months, representing a distinct atoms-to-bits integration strategy from Omada's continuous CGM monitoring. This periodic biomarker testing approach (quarterly) vs. continuous monitoring (daily) represents two different physical-to-digital integration strategies with different cost/adherence tradeoffs. Noom achieved $100M revenue run-rate within four months of launching GLP-1 programs in September 2024, demonstrating that periodic biomarker testing can be commercially viable as a physical integration layer.

inbox/archive/health/2026-04-28-noom-glp1-companion-biomarker-integration-2025.md

@@ -7,10 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: news
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-30
 priority: medium
 tags: [noom, GLP-1, behavioral-support, biomarker, digital-health, adherence, microdose]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content